Heart rate fluctuation after birth predicts subsequent cardiorespiratory stability in preterm infants.
Kerstin Jost, Alexandre N Datta, Urs P Frey...
https://pubmed.ncbi.nlm.nih.gov/31086292/Actively Recruiting
Led by Uludag University · Updated on 2026-05-01
100
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to evaluate whether electroencephalography EEG can reliably assess brain maturation in preterm infants to guide the safe stopping of caffeine therapy without causing a return of apnea. The study focuses on infants born prematurely who are receiving caffeine to manage apnea of prematurity, a condition causing pauses in breathing. The study involves observing infants who have been treated with caffeine. EEG assessments will be conducted when it is time to consider stopping caffeine treatment, to help determine if the infants brain has matured enough to discontinue therapy safely. There are no experimental treatments instead, the study monitors and evaluates EEG data alongside clinical outcomes. Participants will be monitored from enrollment until four weeks after caffeine therapy ends. Researchers will evaluate apnea risk after stopping caffeine by reviewing EEG results and clinical observations. The study includes infants born before 37 weeks gestation who have received caffeine treatment, with follow-up assessments to ensure safety and gather reliable data on apnea recurrence.
CONDITIONS
The Role of Electroencephalography in Caffeine Discontinuation Timing in Premature Infants
S
Salih Çağrı Çakır
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Uludag University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 weeks
Participants are monitored to assess apnea risk after discontinuation of caffeine therapy.
Regular assessments during caffeine therapy discontinuation period
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Kerstin Jost, Alexandre N Datta, Urs P Frey...
https://pubmed.ncbi.nlm.nih.gov/31086292/Eilon Shany, Itai Berger
https://pubmed.ncbi.nlm.nih.gov/21383227/James Ken Jiang, Cui Wang
https://pubmed.ncbi.nlm.nih.gov/39616826/Hasan Özkan, Ömer Erdeve, H Gözde Kanmaz Kutman
https://pubmed.ncbi.nlm.nih.gov/31236018/David G Sweet, Virgilio P Carnielli, Gorm Greisen...
https://pubmed.ncbi.nlm.nih.gov/36863329/Lauren Thompson, Joseph W Werthammer, David Gozal
https://pubmed.ncbi.nlm.nih.gov/39594446/Silvana Am Urru, Milena Geist, Rebecka Carlinger...
https://pubmed.ncbi.nlm.nih.gov/39045901/N J Stevenson, L Oberdorfer, N Koolen...
https://pubmed.ncbi.nlm.nih.gov/29021546/Betul Acunaş, Sinan Uslu, Ahmet Yağmur Baş
https://pubmed.ncbi.nlm.nih.gov/31236031/Siree Kaempfen, Mareike Hug, Carlos Sanchez...
https://pubmed.ncbi.nlm.nih.gov/39805735/Uludag University
Lead Sponsor